AIMC Journal:
Immunotherapy

Immune checkpoint inhibitors (ICIs) have radically changed the treatment landscape of non-small cell lung cancer (NSCLC) and significantly improved patients' prognosis in many settings of the disease. Nevertheless, clinical outcomes remain highly het...

Neoantigens are tumor-specific antigens resulting from genetic, transcriptomic, and proteomic changes, making them a promising avenue for personalized cancer immunotherapy due to their unique specificity and strong immunogenicity. They arise through ...

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but response varies across patients. Gut microbiota may influence immunotherapy outcomes, while artificial intelligence (AI) can help characterize complex microbiome-h...

The gut microbiota (GM) has emerged as a key modulator of cancer development and therapeutic response beyond the gastrointestinal tract. In extra-intestinal cancers, GM composition influences oncogenesis, with specific microbial taxa and their metabo...